Mechanism of Action
Endothelin Receptor Agonism
Sarafotoxins (SRTX-a, -b, -c) bind ETA and ETB receptors with varying selectivity. SRTX-c (sarafotoxin 6c) is highly ETB-selective (>1000-fold over ETA), making it the defining ETB-selective agonist tool compound. ETA receptors mediate vasoconstriction in vascular smooth muscle; ETB receptors mediate vasodilation (via endothelial NO/prostacyclin) and vasoconstriction (via smooth muscle ETB).
Cardiovascular Effects
IV sarafotoxin produces a characteristic biphasic cardiovascular response: an initial transient vasodilation followed by sustained, potent vasoconstriction and increased systemic vascular resistance. Cardiac output falls and coronary vasospasm can occur. These effects mirror endothelin-1 but can be dissected pharmacologically using sarafotoxin isoforms with different receptor selectivities.
Research Summary
ETB Receptor Pharmacology
Research ToolSRTX-c is the standard ETB-selective agonist used to define ETB receptor function in vascular and non-vascular tissues. Studies using SRTX-c established the dual role of ETB receptors: endothelial ETB mediates vasodilation via NO, while smooth muscle ETB mediates vasoconstriction. This contributed directly to the rationale for subtype-selective endothelin receptor antagonists.
Cardiac Ischemia Models
PreclinicalSarafotoxin has been used to model endothelin-induced coronary vasospasm in isolated heart preparations. These models helped establish that endothelin system activation contributes to ischemia-reperfusion injury and validated ECE inhibition as a protective strategy.
Calculate your Sarafotoxin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| ETB receptor activation (vascular prep) | 1-100 nM | Single concentration-response | Tissue bath / perfusate |
| ETB-selective agonism in vivo | 1-10 nmol/kg IV (SRTX-c) | Single bolus | Intravenous |
| Coronary vasospasm model | 0.1-1 nmol/kg IV | Single bolus | Intravenous |
Sarafotoxins are toxic research tools not for human use. They produce lethal cardiovascular effects at suprapharmacological doses.
Interactions
Safety Profile
Sarafotoxins are potent cardiovascular toxins in the context of snake envenomation. IV administration causes coronary vasospasm, severe hypertension, and cardiac arrhythmias. They have no human therapeutic application. Their utility is entirely as in vitro and in vivo pharmacological tools at precisely controlled doses in research settings.
References
- [1]Kloog Y, et al. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988;242(4876):268-270.
- [2]Ihara M, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247-255.
- [3]Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16(8):1081-1098.